Abstract
A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.
Original language | English (US) |
---|---|
Pages (from-to) | 654-655 |
Number of pages | 2 |
Journal | Human Vaccines and Immunotherapeutics |
Volume | 17 |
Issue number | 3 |
DOIs |
|
State | Published - 2021 |
Externally published | Yes |
Keywords
- SARS-CoV-2
- neutralizing antibodies
- receptor-binding domain
- vaccine
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pharmacology